
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7813512/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of Biomarkers to Predict Recurrence by Determining the Metastatic Ability of Cancer Cells. Journal of Nippon Medical School, 2022, 89, 24-32.	0.3	2
2	Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms. Cancer Biomarkers, 2022, 33, 503-512.	0.8	4
3	BP180 Is a Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Anticancer Research, 2021, 41, 1089-1099.	0.5	5
4	Hepatitis B Xâ€interacting protein, involved in increasing proliferation and cell migration, is a prognostic marker in head and neck squamous cell carcinoma. Oral Science International, 2021, 18, 217-228.	0.3	1
5	On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity. Redox Biology, 2021, 41, 101926.	3.9	20
6	PSY8-2 Search of biomarkers and creation of innovative methods required for precision medicine for gastric cancer. Annals of Oncology, 2021, 32, S245.	0.6	0
7	ACTN4 gene amplification is a predictive biomarker for adjuvant chemotherapy with UFT in stage I lung adenocarcinomas. Cancer Science, 2021, , .	1.7	2
8	Prospects for Comprehensive Analyses of Circulating Tumor Cells in Tumor Biology. Cancers, 2020, 12, 1135.	1.7	16
9	Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens. Theranostics, 2020, 10, 2115-2129.	4.6	20
10	Actinin-4 splice variant - a complementary diagnostic and prognostic marker of pancreatic neuroendocrine neoplasms. Journal of Cancer, 2020, 11, 2318-2328.	1.2	4
11	Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma. British Journal of Cancer, 2020, 122, 1811-1817.	2.9	8
12	Multiplexed single-molecule enzyme activity analysis for counting disease-related proteins in biological samples. Science Advances, 2020, 6, eaay0888.	4.7	44
13	Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer. Oncology Letters, 2019, 17, 831-842.	0.8	10
14	Monitoring of cancer patients via nextâ€generation sequencing of patientâ€derived circulating tumor cells and tumor <scp>DNA</scp> . Cancer Science, 2019, 110, 2590-2599.	1.7	57
15	Trends in biomarker discoveries for the early detection and risk stratification of pancreatic cancer using omics studies. Expert Review of Molecular Diagnostics, 2019, 19, 651-654.	1.5	6
16	Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer. Biological and Pharmaceutical Bulletin, 2019, 42, 1766-1771.	0.6	13
17	Metabolomics-based Discovery of Serum Biomarkers to Predict the Side-effects of Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 519-526.	0.5	8
18	Live single cell mass spectrometry reveals cancerâ€specific metabolic profiles of circulating tumor cells. Cancer Science, 2019, 110, 697-706.	1.7	90

#	Article	IF	CITATIONS
19	CA19â€9 and apolipoproteinâ€A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation. International Journal of Cancer, 2019, 144, 1877-1887.	2.3	44
20	Serum apolipoprotein A2 isoforms in autoimmune pancreatitis. Biochemical and Biophysical Research Communications, 2018, 497, 903-907.	1.0	11
21	Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer. Pancreatology, 2018, 18, 624-629.	0.5	4
22	Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach. Biomarkers in Medicine, 2018, 12, 827-840.	0.6	15
23	Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Clinica Chimica Acta, 2017, 468, 98-104.	0.5	38
24	Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. Biomarkers in Medicine, 2017, 11, 721-731.	0.6	15
25	Actinin-1 and actinin-4 play essential but distinct roles in invadopodia formation by carcinoma cells. European Journal of Cell Biology, 2017, 96, 685-694.	1.6	22
26	The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. Oncotarget, 2017, 8, 95083-95094.	0.8	15
27	A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab. Cancer Chemotherapy and Pharmacology, 2016, 78, 567-575.	1.1	1
28	Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. Biomarkers in Medicine, 2016, 10, 1197-1207.	0.6	22
29	Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics. PLoS ONE, 2016, 11, e0161009.	1.1	76
30	Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4. Oncotarget, 2016, 7, 33165-33178.	0.8	22
31	The biological role of actinin-4 (ACTN4) in malignant phenotypes of cancer. Cell and Bioscience, 2015, 5, 41.	2.1	85
32	The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer. Anticancer Research, 2015, 35, 1663-7.	0.5	8
33	Alternative Mammalian Target of Rapamycin (mTOR) Signal Activation in Sorafenib-resistant Hepatocellular Carcinoma Cells Revealed by Array-based Pathway Profiling. Molecular and Cellular Proteomics, 2014, 13, 1429-1438.	2.5	54
34	Immunohistochemical actinin-4 expression in infiltrating gliomas: association with WHO grade and differentiation. Brain Tumor Pathology, 2014, 31, 11-16.	1.1	16
35	Copy number increase of <i>ACTN4</i> is a prognostic indicator in salivary gland carcinoma. Cancer Medicine, 2014, 3, 613-622.	1.3	34
36	Histological growth pattern of and alpha-actinin-4 expression in thyroid cancer. Anticancer Research, 2014, 34, 3157-63.	0.5	14

#	Article	IF	CITATIONS
37	SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Modern Pathology, 2013, 26, 1041-1050.	2.9	146
38	Soluble interleukinâ€6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Science, 2013, 104, 1045-1051.	1.7	41
39	Proteomic Approaches to the Discovery of Cancer Biomarkers for Early Detection and Personalized Medicine. Japanese Journal of Clinical Oncology, 2013, 43, 103-109.	0.6	54
40	Junctional <scp>R</scp> ab13â€binding protein (<scp>JRAB</scp>) regulates cell spreading via filamins. Genes To Cells, 2013, 18, 810-822.	0.5	17
41	Rab13 Small G Protein and Junctional Rab13-binding Protein (JRAB) Orchestrate Actin Cytoskeletal Organization during Epithelial Junctional Development. Journal of Biological Chemistry, 2012, 287, 42455-42468.	1.6	40
42	<i>ACTN4</i> gene amplification and actininâ€4 protein overexpression drive tumour development and histological progression in a highâ€grade subset of ovarian clearâ€cell adenocarcinomas. Histopathology, 2012, 60, 1073-1083.	1.6	35
43	Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Science, 2011, 102, 630-638.	1.7	58
44	Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2195-2203.	1.1	67
45	Combined Functional Genome Survey of Therapeutic Targets for Clear Cell Carcinoma of the Kidney. Japanese Journal of Clinical Oncology, 2011, 41, 847-853.	0.6	1
46	Reduced Plasma Level of CXC Chemokine Ligand 7 in Patients with Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 160-171.	1.1	45
47	Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment. Molecular and Cellular Proteomics, 2010, 9, 695-704.	2.5	33
48	Rab13 Regulates Neurite Outgrowth in PC12 Cells through Its Effector Protein, JRAB/MICAL-L2. Molecular and Cellular Biology, 2010, 30, 1077-1087.	1.1	71
49	Traf2- and Nck-Interacting Kinase Is Essential for Wnt Signaling and Colorectal Cancer Growth. Cancer Research, 2010, 70, 5024-5033.	0.4	109
50	Combined Functional Genome Survey of Therapeutic Targets for Hepatocellular Carcinoma. Clinical Cancer Research, 2010, 16, 2518-2528.	3.2	149
51	Traf2- and Nck-interacting Kinase Is Essential for Canonical Wnt Signaling in Xenopus Axis Formation. Journal of Biological Chemistry, 2010, 285, 26289-26294.	1.6	30
52	Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma. Molecular Cancer Therapeutics, 2010, 9, 535-544.	1.9	111
53	Prolyl 4-Hydroxylation of α-Fibrinogen. Journal of Biological Chemistry, 2009, 284, 29041-29049.	1.6	51
54	Identification of a Predictive Biomarker for Hematologic Toxicities of Gemcitabine. Journal of Clinical Oncology, 2009, 27, 2261-2268.	0.8	40

#	Article	IF	CITATIONS
55	Largeâ€scale quantitative clinical proteomics by labelâ€free liquid chromatography and mass spectrometry. Cancer Science, 2009, 100, 514-519.	1.7	41
56	Quantitative proteomics using formalinâ€fixed paraffinâ€embedded tissues of oral squamous cell carcinoma. Cancer Science, 2009, 100, 1605-1611.	1.7	63
57	Functional genome screen for therapeutic targets of osteosarcoma. Cancer Science, 2009, 100, 2268-2274.	1.7	32
58	Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Modern Pathology, 2009, 22, 499-507.	2.9	77
59	Expression and Gene Amplification of Actinin-4 in Invasive Ductal Carcinoma of the Pancreas. Clinical Cancer Research, 2008, 14, 5348-5356.	3.2	101
60	Mass Spectrometry Analysis of the Native Protein Complex Containing Actinin-4 in Prostate Cancer Cells. Molecular and Cellular Proteomics, 2007, 6, 479-491.	2.5	47
61	Ku70 and Poly(ADP-Ribose) Polymerase-1 Competitively Regulate β-Catenin and T-Cell Factor-4–Mediated Gene Transactivation: Possible Linkage of DNA Damage Recognition and Wnt Signaling. Cancer Research, 2007, 67, 911-918.	0.4	70
62	Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): Up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 257-267.	1.2	99
63	Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Modern Pathology, 2007, 20, 1278-1285.	2.9	73
64	Serum albumin-associated peptides of patients with uterine endometrial cancer. Cancer Science, 2007, 98, 822-829.	1.7	11
65	Increased susceptibility of <i>Sf1</i> ^{+/–} mice to azoxymethaneâ€induced colon tumorigenesis. Cancer Science, 2007, 98, 1862-1867.	1.7	25
66	Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer. Oncology Reports, 2007, 18, 653-7.	1.2	5
67	Label-free Quantitative Proteomics Using Large Peptide Data Sets Generated by Nanoflow Liquid Chromatography and Mass Spectrometry. Molecular and Cellular Proteomics, 2006, 5, 1338-1347.	2.5	179
68	Morphological and transcriptional responses of untransformed intestinal epithelial cells to an oncogenic Î ² -catenin protein. Oncogene, 2005, 24, 3141-3153.	2.6	40
69	E-Cadherin Regulates the Association between \hat{l}^2 -Catenin and Actinin-4. Cancer Research, 2005, 65, 8836-8845.	0.4	107
70	Prognostic Significance of Tissue Factor in Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2005, 11, 2531-2539.	3.2	152
71	Possible Detection of Pancreatic Cancer by Plasma Protein Profiling. Cancer Research, 2005, 65, 10613-10622.	0.4	122
72	Possible Prediction of Chemoradiosensitivity of Esophageal Cancer by Serum Protein Profiling. Clinical Cancer Research, 2005, 11, 8042-8047.	3.2	47

#	Article	IF	CITATIONS
73	Alternative splice variant of actinin-4 in small cell lung cancer. Oncogene, 2004, 23, 5257-5262.	2.6	49
74	Facilitative role of endogenous oxytocin in noradrenaline release in the rat supraoptic nucleus. European Journal of Neuroscience, 2003, 18, 3018-3026.	1.2	38
75	Close association of severe hyponatremia with exaggerated release of arginine vasopressin in elderly subjects with secondary adrenal insufficiency. European Journal of Endocrinology, 2003, 148, 221-226.	1.9	51
76	Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing Arginine–Vasopressin in brattleboro rats. Molecular Therapy, 2003, 8, 895-902.	3.7	29
77	Neuromedin U facilitates oxytocin release from the pituitary via β adrenoceptors. NeuroReport, 2003, 14, 1997-2000.	0.6	13
78	A suspected case of palatine T-cell lymphoma Nihon Koku Geka Gakkai Zasshi, 2002, 48, 310-313.	0.0	1
79	Arginine vasopressin inhibits apoptosis of rat glomerular mesangial cells via V1a receptors. Life Sciences, 2001, 68, 1485-1493.	2.0	13
80	Vasopressin differentially modulates noradrenaline release in the rat supraoptic nucleus. NeuroReport, 2001, 12, 3509-3511.	0.6	5
81	Medullary A1 noradrenergic neurones may mediate oxytocin release after noxious stimuli. NeuroReport, 2001, 12, 2499-2502.	0.6	21
82	Growth Hormone-Releasing Hormone and Morphine Attenuate Growth Hormone Secretagogue-Induced Activation of the Arcuate Nucleus in the Male Rat. Neuroendocrinology, 1999, 70, 101-106.	1.2	2
83	Association of CTLA-4 polymorphism with positive anti-GAD antibody in Japanese subjects with type 1 diabetes mellitus. Clinical Endocrinology, 1999, 51, 793-799.	1.2	21
84	Inhibition by Transforming Growth FactorBETA.1 of the Cellular Action of Arginine Vasopressin in Cultured Rat Glomerular Mesangial Cells Hypertension Research, 1999, 22, 173-180.	1.5	1
85	Actinin-4, a Novel Actin-bundling Protein Associated with Cell Motility and Cancer Invasion. Journal of Cell Biology, 1998, 140, 1383-1393.	2.3	408
86	A case of an HIV infected patient discovered during dental treatment Nihon Koku Geka Gakkai Zasshi, 1998, 44, 1002-1004.	0.0	3
87	Somatostatin Receptor Subtype 2 Knockout Mice Are Refractory to Growth Hormone-Negative Feedback on Arcuate Neurons. Molecular Endocrinology, 1997, 11, 1709-1717.	3.7	152
88	Galactorrhoea and amenorrhoea due to an intradural neurinoma originating from a thoracic intercostal nerve radicle. Clinical Endocrinology, 1997, 46, 631-636.	1.2	11
89	Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis. Clinical Endocrinology, 1997, 47, 215-221.	1.2	43
90	Cellular signaling and proliferative action of AVP in mesangium of SHR: Effect of low density lipoprotein. Kidney International, 1996, 50, 1506-1514.	2.6	4

#	Article	IF	CITATIONS
91	Inhibition by Adrenomedullin of Arginine Vasopressin-Activated Mitogen-Activated Protein Kinase in Rat Glomerular Mesangial Cells via cAMP Production Hypertension Research, 1996, 19, 113-119.	1.5	6
92	A case of spindle cell carcinoma of the bilateral mandibular gingiva Nihon Koku Geka Gakkai Zasshi, 1994, 40, 1181-1183.	0.0	1
93	The Role of Central Vasopressin in the Development of Stress-Induced Gastric Ulcer. Annals of the New York Academy of Sciences, 1993, 689, 597-599.	1.8	Ο